BioWorld Asia

Sep. 11, 2002

Kudos Raises £30M For Clinical Development Of Cancer Drugs

LONDON - Kudos Pharmaceuticals Ltd. raised £29.5 million (US$45.9 million) in third-round funding with plans to take its two lead cancer treatments through Phase II and push further compounds into Phase I. (Bioworld International Read More

With New Premises, Tropos Launches € 15M Funding Round

No Abstract Read More

Gene Deletion From Colorectal Tumors Might Dictate Success

Session Examines Avoiding Legal Pitfalls In Clinical Trials

Committee Provides Support For European Biotechnology

EU Legislation On GMO Exports Weak, Parliament Member Says

Medivir To Lose CEO Frick To Venture Capital Fund

MediGene Reports Positive Early Results In Liver Cancer

Avidex Third Round Raises £11.5M For T-Cell Receptors

New Controls On Genetically Modified Animals Needed In UK

ScanBalt BioRegion Looking To Create Global Biotech Region

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

BioWorld Science

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...